Geode Capital Management
SPRY icon

Geode Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Geode Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.6M Buy
1,699,017
+172,193
+11% +$1.48M ﹤0.01% 2371
2026
Q1 		$12.3M Sell
1,526,824
-26,046
-2% -$250K ﹤0.01% 2266
2025
Q4 		$18.1M Buy
1,552,870
+47,253
+3% +$460K ﹤0.01% 2063
2025
Q3 		$15.1M Buy
1,505,617
+163,230
+12% +$2.34M ﹤0.01% 2157
2025
Q2 		$23.4M Buy
1,342,387
+81,910
+6% +$1.18M ﹤0.01% 1880
2025
Q1 		$15.9M Buy
1,260,477
+22,321
+2% +$269K ﹤0.01% 2024
2024
Q4 		$13.1M Buy
1,238,156
+3,351
+0.3% +$46.9K ﹤0.01% 2194
2024
Q3 		$17.9M Buy
1,234,805
+38,927
+3% +$463K ﹤0.01% 2033
2024
Q2 		$10.2M Buy
1,195,878
+319,207
+36% +$2.83M ﹤0.01% 2316
2024
Q1 		$8.96M Buy
876,671
+11,802
+1% +$88K ﹤0.01% 2389
2023
Q4 		$4.74M Buy
864,869
+61,528
+8% +$270K ﹤0.01% 2726
2023
Q3 		$3.04M Buy
803,341
+149,746
+23% +$983K ﹤0.01% 2898
2023
Q2 		$4.38M Buy
653,595
+249,991
+62% +$1.67M ﹤0.01% 2758
2023
Q1 		$2.63M Buy
403,604
+71,408
+21% +$549K ﹤0.01% 2918
2022
Q4 		$2.83M Buy
332,196
+107,812
+48% +$700K ﹤0.01% 2924
2022
Q3 		$1.18M Buy
224,384
+732
+0.3% +$3.61K ﹤0.01% 3306
2022
Q2 		$948K Sell
223,652
-138,988
-38% -$485K ﹤0.01% 3452
2022
Q1 		$1.27M Sell
362,640
-29,472
-8% -$128K ﹤0.01% 3500
2021
Q4 		$2.61M Buy
392,112
+207,000
+112% +$1.68M ﹤0.01% 3249
2021
Q3 		$1.85M Sell
185,112
-35,576
-16% -$877K ﹤0.01% 3387
2021
Q2 		$6.82M Buy
220,688
+2,067
+0.9% +$66.3K ﹤0.01% 2724
2021
Q1 		$9.54M Buy
218,621
+199,391
+1,037% +$9.44M ﹤0.01% 2397
2020
Q4 		$891K Buy
+19,230
New +$642K ﹤0.01% 3399

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management's SPRY Position: Q2 2026 in Review

Geode Capital Management increased its ARS Pharmaceuticals (SPRY) stake by 11% in Q2 2026, buying an estimated $1.48M and bringing the position to 1,699,017 shares worth $13.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2371.

Geode Capital Management first reported a position in SPRY in Q4 2020 and has held it in 23 quarters since. The position peaked at $23.4M in Q2 2025. 206 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Geode Capital Management held 1,699,017 shares of ARS Pharmaceuticals worth $13.6M as of Q2 2026.
  • Geode Capital Management bought 172,193 ARS Pharmaceuticals shares in Q2 2026, an estimated $1.48M.
  • ARS Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2371 holding.
  • Geode Capital Management first reported a position in ARS Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Geode Capital Management's ARS Pharmaceuticals position peaked at $23.4M in Q2 2025.
  • 206 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.